





~4h 10m left



TREATMENT GOALS FOR ISCHEMIC STROKE

Adult Suspected Stroke Algorithm


Below you can see key steps in the **Adult Suspected Stroke Algorithm**. This reviews the critical in-hospital time periods for patient assessment and treatment:

- 1 Immediate general and neurologic assessment by the hospital or stroke team, emergency physician, or another expert, ideally upon arrival and within 10 minutes after arrival:
 - Activate stroke team upon EMS notification, prepare for emergent CT scan or MRI of brain upon arrival. Stroke team meets EMS on arrival.
 - Assess ABCs and give oxygen if needed. Obtain IV access and perform laboratory assessments; check glucose and treat if indicated.
 - Review patient history, medications, and procedures. Establish time of symptom onset or last known normal.

1

NEXT












- Review patient history, medications, and procedures. Establish time of symptom onset or last known normal.


TREATMENT GOALS FOR ISCHEMIC STROKE


- Perform physical exam and neurologic examination, including NIH Stroke Scale or Canadian Neurological Scale.
- 2 Neurologic assessment by the stroke team or designee and noncontrast computed tomography (NCCT) scan or MRI performed within 20 minutes after hospital arrival (ideally EMS goes directly to computed tomography CT/MRI suite from the field)
- 3 Interpretation of the NCCT/MRI within 45 minutes after ED/brain imaging suite arrival
- 4 Initiation of fibrinolytic therapy in appropriate patients (those without contraindications) within 45 minutes after hospital arrival
- 5 Door-to-device times within 90 minutes for direct arriving patients and 60 minutes for transfer patients
- 6 Door-in to door-out times for patients being transferred for possible EVT within 60 minutes


2 NEXT



























































You can exit your exercise by clicking on this link >>

Exit Exercise









~4h 10m left





ELIGIBILITY FOR ALTEPLASE THERAPY

Fibrinolytic Therapy

The AHA/ASA 2019 Guidelines for the Early Management of Patients With Acute Ischemic Stroke recommends giving IV alteplase to patients with acute ischemic stroke who meet the current eligibility criteria if it is given by:

- Physicians using a clearly defined institutional protocol
- A knowledgeable interdisciplinary team familiar with stroke care
- An institution with a commitment to quality stroke care

Studies have demonstrated that there is a higher likelihood of good to excellent functional outcome when alteplase is given to














8% PROGRESS: HeartCode ACLS 2025

~4h 10m left





ELIGIBILITY FOR ALTEPLASE THERAPY

alteplase to patients with acute ischemic stroke who meet the current eligibility criteria if it is given by:

- Physicians using a clearly defined institutional protocol
- A knowledgeable interdisciplinary team familiar with stroke care
- An institution with a commitment to quality stroke care

Studies have demonstrated that there is a higher likelihood of good to excellent functional outcome when alteplase is given to adults with acute ischemic stroke within 3 hours after onset of symptoms, or within 4.5 hours after onset of symptoms for selected patients. Evidence from prospective randomized studies in adults also documents a greater likelihood of benefit the earlier treatment begins.
















ELIGIBILITY FOR ALTEPLASE THERAPY

~4h 10m left


Evaluation for Fibrinolytic Therapy


If the CT/MRI scan is negative for hemorrhage, the patient may be a candidate for fibrinolytic therapy.

Immediately perform further eligibility and risk stratification:

- If the CT/MRI scan shows no hemorrhage, the probability of acute ischemic stroke remains. Review inclusion and exclusion criteria for IV fibrinolytic therapy and repeat the neurologic exam (NIHSS or Canadian Neurological Scale).
- If the patient's neurologic function is rapidly improving to normal, fibrinolytics may be unnecessary.









Inclusion and Exclusion Characteristics of Patients With Ischemic Stroke Who Could Be Treated With Alteplase Within 3 Hours After Symptom Onset and Extended Window for Select Patient From 3 to 4.5 Hours*

Indications (COR I)	
Within 3 hours†	IV alteplase (0.9 mg/kg, maximum dose 90 mg over 60 minutes with initial 10% of dose given as bolus over 1 minute) is recommended for selected patients who may be treated within 3 hours of ischemic stroke symptom onset or patient last known well or at baseline state. Physicians should review the criteria outlined in this table to determine patient eligibility.‡ (COR I; LOE A)
Within 3 hours—Age	For otherwise medically eligible patients ≥18 years of age, IV alteplase administration within 3 hours is equally recommended for patients ≤80 and >80 years of age.‡ (COR I; LOE A)
Within 3 hours—Severe stroke	For severe stroke, IV alteplase is indicated within 3 hours from symptom onset of ischemic stroke. Despite increased risk of hemorrhagic transformation, there is still proven clinical benefit for patients with severe stroke symptoms.‡ (COR I; LOE A)
Within 3 hours—Mild disabling stroke	For otherwise eligible patients with mild but disabling stroke symptoms, IV alteplase is recommended for patients who can be treated within 3 hours of ischemic stroke symptom onset or patient last known well or at baseline state (COR I; LOE B-R)§
ВР	IV alteplase is recommended in patients with BP <185/110 mm Hg and in those patients whose BP can be lowered safely to this level with antihypertensive agents, with the physician assessing the stability of the BP before starting IV alteplase.‡ (COR



	quite low; thus, starting IV alteplase is probably recommended in preference over delaying treatment to pursue additional diagnostic studies.‡ (COR IIa; LOE B-NR)II
Stroke mimics	The risk of symptomatic intracranial hemorrhage in the stroke mimic population is
	and potentially disabled in the judgment of the examiner.‡ (COR IIa; LOE A)
	ischemic stroke and demonstrate early improvement but remain moderately impaired
Early improvement	IV alteplase treatment is reasonable for patients who present with moderate to severe
	signal change on FLAIR. (COR IIa; LOE B-R)§
	who have a DW-MRI lesion smaller than one third of the MCA territory and no visible
	have unclear time of onset >4.5 hours from last known well or at baseline state and
	recognition can be beneficial in patients with AIS who awake with stroke symptoms or
Wake-up and unknown time of onset	IV alteplase (0.9 mg/kg, maximum dose 90 mg over 60 minutes with initial 10% of dose given as bolus over 1 minute) administered within 4.5 hours of stroke symptom
(COR IIa)	
Additional recommendations for treatment with IV alteplace for patients with AIS	And (COR IIb)
	NCCT of mild to moderate extent (other than frank hypodensity).‡ (COR I; LOE A)
СТ	IV alteplase administration is recommended in the setting of early ischemic changes or
	I; LOE B-NR)II
	with the physician assessing the stability of the BP before starting IV alteplase.‡ (COR
	patients whose BP can be lowered safely to this level with antihypertensive agents,
BP	IV alteplase is recommended in patients with BP <185/110 mm Hg and in those



Stroke mimics	The risk of symptomatic intracranial hemorrhage in the stroke mimic population is
	quite low; thus, starting IV alteplase is probably recommended in preference over
	delaying treatment to pursue additional diagnostic studies.‡ (COR IIa; LOE B-NR)II
Contraindications (COR III: No Benefit)*	And (COR III: Harm)
0 - to 4.5-hour window—Mild nondisabling stroke	For otherwise eligible patients with mild nondisabling stroke (NIHSS score 0-5). IV
	alteplase is not recommended for patients who could be treated within 3 and 4.5
	hours of ischemic stroke symptom onset or patient last known well or at baseline
	state. (COR III: No Benefit, LOE B-R)§
СТ	There remains insufficient evidence to identify a threshold of hypoattenuation severity
	or extent that affects treatment response to alteplase. However, administering IV
	alteplase to patients whose CT brain imaging exhibits extensive regions of clear
	hypoattenuation is not recommended. These patients have a poor prognosis despite N
	alteplase, and severe hypoattenuation defined as obvious hypodensity represents
	irreversible injury.‡ (COR III: No Benefit; LOE A)¶
ICH	IV alteplase should not be administered to a patient whose CT reveals an acute
	intracranial hemorrhage.‡ (COR III: Harm; LOE C-EO)II¶
Ischemic stroke within 3 months	Use of IV alteplase in patients presenting with AIS who have had a prior ischemic
	stroke within 3 months may be harmful.‡ (COR III: Harm; LOE B-NR)II¶
Severe head trauma within 3 months	In AIS patients with recent severe head trauma (within 3 months), IV alteplase is
	contraindicated.‡ (COR III: Harm; LOE C-EO)II¶
Acute head trauma	Given the possibility of bleeding complications from the underlying severe head
	trauma, IV alteplase should not be administered in posttraumatic infarction that occurs



Acute head trauma	Given the possibility of bleeding complications from the underlying severe head
	trauma, IV alteplase should not be administered in posttraumatic infarction that occurs
	during the acute in-hospital phase.‡ (COR III: Harm; LOE C-EO)II¶ (Recommendation
	wording modified to match COR III stratifications.)
Intracranial/intraspinal surgery within 3 months	For patients with AIS and a history of intracranial/spinal surgery within the prior 3
	months, IV alteplase is potentially harmful.‡ (COR III: Harm; LOE C-EO)Ⅱ¶
History of intracranial hemorrhage	IV alteplase administration in patients who have a history of intracranial hemorrhage is
	potentially harmful.‡ (COR III: Harm; LOE C-EO)II¶
Subarachnoid hemorrhage	IV alteplase is contraindicated in patients presenting with symptoms and signs most
	consistent with an SAH.‡ (COR III: Harm; LOE C-EO)II¶
GI malignancy or GI bleed within 21 days	Patients with a structural GI malignancy or recent bleeding event within 21 days of
	their stroke event should be considered high risk, and IV alteplase administration is
	potentially harmful.‡ (COR III: Harm; LOE C-EO)II¶
Coagulopathy	The safety and efficacy of IV alteplase for acute stroke patients with platelets <100
	000/mm³, INR >1.7, aPTT >40 seconds, or PT >15 seconds are unknown, and IV
	alteplase should not be administered.‡ (COR III: Harm; LOE C-EO)II¶
	(In patients without history of thrombocytopenia, treatment with IV alteplase can be
	initiated before availability of platelet count but should be discontinued if platelet
	count is <100 000/mm ³ . In patients without recent use of OACs or heparin, treatment
	with IV alteplase can be initiated before availability of coagulation test results but
	should be discontinued if INR is >1.7 or PT is abnormally elevated by local laboratory
	standards.) (Recommendation wording modified to match COR III stratifications.)
LMWH	IV alteplase should not be administered to patients who have received a full treatment



	should be discontinued if Tink is >1 / or PT is abnormally elevated by local laboratory standards.) (Recommendation wording modified to match COR III stratifications.)
LMWH	IV alteplase should not be administered to patients who have received a full treatment dose of LMWH within the previous 24 h.‡ (COR III: Harm; LOE B-NR)§II (Recommendation wording modified to match COR III stratifications.)
Thrombin inhibitors or factor Xa inhibitors	The use of IV alteplase in patients taking direct thrombin inhibitors or direct factor Xa inhibitors has not been firmly established but may be harmful.‡ (COR III: Harm; LOE C-EO)II¶ IV alteplase should not be administered to patients taking direct thrombin inhibitors or direct factor Xa inhibitors unless laboratory tests such as aPTT, INR, platelet count, ecarin clotting time, thrombin time, or appropriate direct factor Xa activity assays are normal or the patient has not received a dose of these agents for >48 hours (assuming normal renal metabolizing function). (Alteplase could be considered when appropriate laboratory tests such as aPTT, INR, ecarin clotting time, thrombin time, or direct factor Xa activity assays are normal or when the patient has not taken a dose of these ACs for >48 hours and renal function is normal.) (Recommendation wording modified to match COR III stratifications.)
Concomitant Abciximab	Abciximab should not be administered concurrently with IV alteplase. (COR III: Harm; LOE B-R)§

Alteplase Considerations in the 3- to 4.5-Hour Time Window in Addition to Those in the 0- to 3-Hour Window

Indications (COR 1)	
2 15 hourst	Walton aco 10.0 marks mayin in doco 90 ma over 60 min with initial 10% of doco



Alteplase Considerations in the 3- to 4.5-Hour Time Window in Addition to Those in the 0- to 3-Hour Window

Indications (COR 1)	
3-4.5 hours†	IV alteplase (0.9 mg/kg, maximum dose 90 mg over 60 min with initial 10% of dose given as bolus over 1 min) is also recommended for selected patients who can be treated within 3 and 4.5 hours of ischemic stroke symptom onset or patient last known well. Physicians should review the criteria outlined in this table to determine patient eligibility.‡ (COR 1; LOE B-R)II
3-4.5 hours-Age	IV alteplase treatment in the 3- to 4.5-hour time window is recommended for those patients ≤80 years of age, without a history of both diabetes mellitus and prior stroke, NIHSS score ≤25, not taking any OACs, and without imaging evidence of ischemic injury involving more than one third of the MCA territory.‡ (COR 1; LOE B-R)II
Additional recommendations for treatment with IV alteplase for patients with AIS	And (COR 2b)
(COR 2a)	
3-4.5 hours-Age	For patients >80 years of age presenting in the 3- to 4.5-hour window, IV alteplase is safe and can be as effective as in younger patients.‡ (COR 2a; LOE B-NR)II
3-4.5 hours—Diabetes mellitus and prior stroke	In AIS patients with prior stroke and diabetes mellitus presenting in the 3- to 4.5- hour window, IV alteplase may be as effective as treatment in the 0- to 3-hour window and may be a reasonable option.‡ (COR 2b; LOE B-NR)II
3-4.5 hours—Severe stroke	The benefit of IV alteplase between 3 and 4.5 hours from symptom onset for patients with very severe stroke symptoms (NIHSS score >25) is uncertain.‡ (COR 2b; LOE C-



	NIHSS score ≤25, not taking any OACs, and without imaging evidence of ischemic injury involving more than one third of the MCA territory.‡ (COR 1; LOE B-R)II
Additional recommendations for treatment with IV alteplase for patients with AIS (COR 2a)	And (COR 2b)
3-4.5 hours-Age	For patients >80 years of age presenting in the 3- to 4.5-hour window, IV alteplase is safe and can be as effective as in younger patients.‡ (COR 2a; LOE B-NR)II
3-4.5 hours—Diabetes mellitus and prior stroke	In AIS patients with prior stroke and diabetes mellitus presenting in the 3- to 4.5- hour window, IV alteplase may be as effective as treatment in the 0- to 3-hour window and may be a reasonable option.‡ (COR 2b; LOE B-NR)II
3-4.5 hours—Severe stroke	The benefit of IV alteplase between 3 and 4.5 hours from symptom onset for patients with very severe stroke symptoms (NIHSS score >25) is uncertain.‡ (COR 2b; LOE C-LD)II
3 -4.5 hours—Mild disabling stroke	For otherwise eligible patients with mild disabling stroke, IV alteplase may be reasonable for patients who can be treated within 3 and 4.5 hours of ischemic stroke symptom onset or patient last known well or at baseline state. (COR 2b; LOE B-NR)§

Abbreviations: AC, anticoagulants; AIS, acute ischemic stroke; aPTT, activated partial thromboplastin time; BP, blood pressure; COR, Class of Recommendation; CT, computed tomography; DW-MRI, diffusion-weighted magnetic resonance imaging; FLAIR, fluid-attenuated inversion recovery; GI, gastrointestinal; ICH, intracerebral hemorrhage; INR, international normalized ratio; IV, intravenous; LMWH, low-molecular-weight heparin; LOE, Level of Evidence; MCA, middle cerebral artery; NCCT, noncontrast computed tomography; NIHSS, National Institutes of Health Stroke Scale; OAC, oral anticoagulant; PT, prothromboplastin time.

*The relative contraindications are abbreviated. Modified from Table 8 in the "Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the

Abbreviations: AC, anticoagulants; AIS, acute ischemic stroke; aPTT, activated partial thromboplastin time; BP, blood pressure; COR, Class of Recommendation; CT, computed tomography; DW-MRI, diffusion-weighted magnetic resonance imaging: FLAIR, fluid-attenuated inversion recovery; GI, gastrointestinal; ICH, intracerebral hemorrhage; INR, international normalized ratio; IV, intravenous; LMWH, low-molecular-weight heparin; LOE, Level of Evidence; MCA, middle cerebral artery; NCCT, noncontrast computed tomography; NIHSS, National Institutes of Health Stroke Scale; OAC, oral anticoagulant; PT, prothromboplastin time.

*The relative contraindications are abbreviated. Modified from Table 8 in the "Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: a Guideline for Healthcare Professionals from the American Heart Association/American Stroke
Association." Please see Table 8 for a full listing of specific considerations.

†When uncertain, the time of onset time should be considered the time when the patient was last known to be normal or at baseline neurological condition.

‡Recommendation unchanged or reworded for clarity from 2015 IV Alteplase. See Table XCV in online Data Supplement 1 for original wording.

§See also the text of these guidelines for additional information on these recommendations.

II LOE amended to conform with American College of Cardiology/AHA 2015 Recommendation Classification System.

¶COR amended to conform with American College of Cardiology/AHA 2015 Recommendation Classification System.


Unless otherwise specified, these eligibility recommendations apply to patients who can be treated within 0 to 4.5 hours of ischemic stroke symptom onset or patient last known well or at baseline state.


Clinicians should also be informed of the indications and contraindications from local regulatory agencies (for current information from the US Food and Drug Administration refer to http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/103172s5203lbl.pdf).

For a detailed discussion of this topic and evidence supporting these recommendations, refer to the AHA scientific statement on the rationale for inclusion and exclusion criteria for IV alterplase in AIS.

CLOSE







PROGRESS: HeartCode ACLS 2025

~4h 11m left



ELIGIBILITY CRITERIA FOR ENDOVASCULAR THERAPY

Although IV alteplase remains as a first-line treatment, the AHA now recommends endovascular therapy for select patients with acute ischemic stroke due to an LVO.

As with fibrinolytic therapy, patients must meet inclusion criteria to be considered for this treatment. Similarly, better clinical outcomes are associated with reduced times from symptom onset to reperfusion, but these new treatment options offer the added benefit of expanding the treatment window up to 24 hours from the onset of symptoms.



Mechanical Thrombectomy With Stent Retrievers

Patients arriving within 6 hours after symptom onset should receive endovascular therapy with a stent retriever if they meet all of the following criteria:



38%

PROGRESS: HeartCode ACLS 2025

~4h 11m left







Coach



Push ▶ for reading content aloud.

Autoplay



On

Mechanical Thrombectomy With Stent Retrievers

Patients arriving within 6 hours after symptom onset should receive endovascular therapy with a stent retriever if they meet all of the following criteria:

ELIGIBILITY CRITERIA FOR ENDOVASCULAR THERAPY

- Prestroke modified Rankin Score of 0 to 1
- Causative LVO of the internal carotid artery or proximal middle cerebral artery demonstrated on cerebrovascular imaging
- Age 18 years or older
- NIHSS score of 6 or greater
- Alberta Stroke Program Early CT Score (ASPECTS) of 6 or greater. (ASPECTS is an early, reliable tool that uses a 10-point quantitative topographic CT scan score to determine early ischemic changes)
- Treatment can be initiated (groin puncture) within 6 hours after symptom onset or last known normal



GOT IT NOW

































GENERAL STROKE CARE


The general care of all patients with stroke includes the following actions:

- Begin acute stroke pathway
- Assess ABCs, and give oxygen if needed
- Monitor blood glucose
- Monitor blood pressure
- Monitor temperature
- Perform dysphagia screening
- Monitor for complications of stroke and fibrinolytic therapy
- Transfer to a higher level of care (EVT, neurologic intensive care unit) if indicated


1 2 3 4 NEXT













Monitor for Complications of Stroke and Fibrinolytic Therapy

Hyperglycemia is associated with worse clinical outcome in patients with acute ischemic stroke. But there is no direct evidence


There is evidence that insulin treatment of hyperglycemia in other critically ill patients improves survival rates. For this reason, consider giving IV or subcutaneous insulin to lower blood glucose in patients with acute ischemic stroke when the serum



NEXT



of bleeding.





Monitor the patient for signs of increased intracranial pressure. Continue to control blood pressure to reduce the potential risk


CHALLENGE US

PREVIOUS












GENERAL STROKE CARE


Because the maximum interval from the onset of stroke until effective treatment of stroke with alteplase is limited, most patients with sustained hypertension above these levels will not be eligible for IV alteplase.

Managing arterial hypertension in patients not undergoing reperfusion strategies remains challenging. Data to guide recommendations for treatment are inconclusive or conflicting. Many patients have spontaneous declines in blood pressure during the first 24 hours after onset of stroke.


By clicking on the button below, you will be able to review potential approaches to arterial hypertension in acute ischemic stroke patients who are candidates for acute reperfusion therapy.














You can exit your exercise by clicking on this link >>

Exit Exercise














Introduction


A 74-year-old man experienced left-arm weakness and left-sided facial paralysis when he woke up this morning. He has a past medical history of poorly controlled hypertension.

CHALLENGE US























































































































Think So

